Last Updated : October 30, 2024
Details
FilesGeneric Name:
rivaroxaban
Project Status:
Complete
Therapeutic Area:
Venous thromboembolic events (VTE)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0750-000 - SR0750-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
N/A
Indications:
Treatment of venous thromboembolic events (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation treatment.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
| Call for patient/clinician input open | July 14, 2022 |
|---|---|
| Call for patient/clinician input closed | September 02, 2022 |
| Clarification: - No patient input submission received | |
| Call for industry input open | July 14, 2022 |
| Call for industry input closed | September 02, 2022 |
| Review initiated | October 12, 2022 |
| Expert committee meeting (initial) | August 24, 2023 |
| Draft recommendation posted for stakeholder feedback | - |
| End of feedback period | October 06, 2023 |
| Final recommendation posted | October 30, 2023 |
| Canada's Drug Agency review report(s) posted | September 21, 2023 |
Files
Last Updated : October 30, 2024